Oryzon Genomics SA (ORY) — Cash Flow Quality Index

Latest as of June 2023: -2.29x

Oryzon Genomics SA (ORY) has a Cash Flow Quality Index of -2.29x as of June 2023. Operating cash flow of €-2.41 Million is below net income of €1.05 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore cash efficiency ratio of Oryzon Genomics SA to assess how effectively this company generates cash.

Cash Flow Quality Index

-2.29x
Operating CF / Net Income

Operating Cash Flow

€-2.41 Million
EUR

Net Income

€1.05 Million
EUR

Data as of

Jun 2023
Most recent filing

Oryzon Genomics SA Cash Flow Quality Index (2014–2014)

Historical Cash Flow Quality Index for Oryzon Genomics SA across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check ORY cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Annual Cash Flow Quality Index for Oryzon Genomics SA (2014–2014)

Year-by-year earnings quality comparison for Oryzon Genomics SA. For live market cap and the full company financial profile, see Oryzon Genomics SA market capitalisation.

Year Quality Index Operating CF (EUR) Net Income YoY Change
2014 1.82x €12.13 Million €6.65 Million
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.